Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
about
Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and SafetyVaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesNear real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methodsThe Pioneering Role of the Vaccine Safety Datalink Project (VSD) to Advance Collaborative Research and Distributed Data NetworksA Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety SurveillanceGuillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.Association rule mining in the US Vaccine Adverse Event Reporting System (VAERS).Relationship between the population incidence of febrile convulsions in young children in Sydney, Australia and seasonal epidemics of influenza and respiratory syncytial virus, 2003-2010: a time series analysis.A Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data.A retrospective population-based study on seizures related to childhood vaccination.A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series designImpact of computerized provider order entry (CPOE) on length of stay and mortalityRisk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study.Adverse events following 12 and 18 month vaccinations: a population-based, self-controlled case series analysisChallenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Successes and challenges in varicella vaccineRecent Research on Febrile Seizures: A Review.Prophylactic antipyretics for prevention of febrile seizures following vaccinationGenetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccinationGuillain-Barré syndrome incidence in a large United States cohort (2000-2009).Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013Kaiser Permanente Vaccine Study Center: Highlights of 2009-2012.Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population.Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.Physicians' confidence in vaccine safety studiesSafety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.Vaccine effectiveness evaluation during a varicella outbreak among children of primary schools and day-care centers in a region which adopted UMVContinuous versus group sequential analysis for post-market drug and vaccine safety surveillance.Nonfebrile seizures after mumps, measles, rubella, and varicella-zoster virus combination vaccination with detection of measles virus RNA in serum, throat, and urine.Efficacy of varicella (VZV) vaccination: an update for the clinician.A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative processIssues in pediatric vaccine-preventable diseases in low- to middle-income countriesComposite sequential Monte Carlo test for post-market vaccine safety surveillance.Vaccine Safety Surveillance Systems: Critical Elements and Lessons Learned in the Development of the US Vaccine Safety Datalink's Rapid Cycle Analysis Capabilities.An observational study of febrile seizures: the importance of viral infection and immunization.Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children.
P2860
Q26778207-32917F12-368E-44D9-B518-E8343E46A57FQ26796420-E2EC2F4C-5E1F-4CE3-B5E2-0EC17FB70639Q28075754-960F8BCB-9BB8-4AE8-91EF-485C51A254D4Q28602789-A77943D3-5E4E-4E72-80AB-2E28C0B1224EQ29031025-CFD175A9-6CE7-41B9-A04F-241F2869B731Q30351998-39EBD6CA-928D-4979-9140-17D37F275CF8Q30375323-DE6B48A6-8D87-4B25-8FA5-3E8142698B85Q30408657-47CE2678-48B9-4820-BE08-C28E22BDBBDAQ31135365-B544E731-AEA1-4754-94CE-26F6AAF3295BQ33160174-646BBE1E-2642-4D5A-A41A-BE95D54087F9Q33405209-265894BD-F266-467D-944C-23A305A6E94BQ33564851-216A984D-8884-4AAC-961F-535FB0E6BD3CQ33990235-1D7E4DC4-BBDB-4F67-B398-DA5DAA4B79B9Q34102900-BEAE1F0C-60D3-4656-BF18-35B25DD72A1DQ34133842-0530421D-250A-48BC-B56C-0BB19B1582BEQ34133849-8E3B2772-AC03-4BB4-8733-B85EBA61052DQ34133896-D06BA47E-A660-486E-805C-447336FCC6CDQ34390072-E2667FF5-6252-4E0E-A4D0-72F8872DF67DQ34416710-A6FF0ECE-071E-44B2-90A6-1942CC767E5AQ34452671-56F7DCF1-DDA3-49B8-BC3F-28845ED14D6BQ34551442-E74D178F-DD08-4767-B607-FE952AB97CDDQ34599856-E6A74394-3C12-49A4-9023-57ECD122B7DFQ34640979-DB4C1710-62A0-4A0D-91E4-51F0E0BBE839Q35661817-AA38BFFA-DA59-4CC4-B674-EC26920F4994Q35890630-5B4D77BE-868C-474F-BD74-70B9EF420382Q35991578-FC994AAA-671C-40E4-9238-80FD70B01AE7Q36171295-AB04F7EB-E367-44C7-8B26-2FD28C9B6577Q36171675-3E18E1E2-9FDC-487F-80C1-26E3F1DE220FQ36175636-6634405B-7B85-46DB-A84D-74045A43B623Q36377372-283E9EFB-8C41-4A61-80D1-1B5DB9C295EEQ36887989-BBD87F18-A06B-400E-99AE-35C27B9EDE65Q36955813-531C4914-FF86-42D4-BD73-3B846852A8D6Q36970261-75E3B749-72F2-44D4-A552-C8635C217BFDQ37158220-B53A450D-8CF8-4E99-A415-214213061227Q37197033-68BBE0AC-1F8C-4CD0-A565-FC0BFF456653Q37264972-C114C7D5-0574-43EC-AD30-5B6C2655C1F8Q37315456-67ADC89D-2DCE-4221-83BA-779A97B44E90Q37327861-E5B0D3D6-D4DB-4B49-B700-99AE93FBBFA2Q37470267-85BE583C-BA6E-43E0-AA7D-5A9085F6ECFDQ37473550-8E485491-3852-4D4A-A595-4A0F95494148
P2860
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@ast
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@en
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@nl
type
label
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@ast
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@en
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@nl
prefLabel
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@ast
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@en
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@nl
P2093
P50
P3181
P356
P1433
P1476
Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures
@en
P2093
Allison Naleway
Bruce Fireman
Edwin Lewis
Eric Weintraub
James Baggs
James Nordin
Roger Baxter
Simon Hambidge
Tracy Lieu
P3181
P356
10.1542/PEDS.2010-0665
P407
P577
2010-07-01T00:00:00Z